셀레믹스

331920KOSDAQ기초 의약물질 제조업

57.5 / 100

Reference Date: 2026-06-10

Financial Score19.0 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Rose 5.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Cellomics is a company specializing in DNA sequencing and molecular cloning technologies based on molecular biology, utilizing its innovative MSSIC (Massively Separated and Sequence Identified Cloning) technology to enable low-cost, high-throughput analysis. The company offers key products such as Target Capture kits, immune repertoire analysis solutions, and next-generation sequencing solutions, which are widely used in healthcare, pharmaceuticals, agriculture, and other fields.

Number of Employees

41people

Average Salary

60.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 27.714.0Point

PBR

6.38Industry Average 1.740.0Point

3.7x industry avg (risky)

ROE

-16.08Industry Average -6.033.5Point

2.7x industry avg (excellent)

Debt Ratio

0.48Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼6.0% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.8% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 6.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (79%)

Current 15,000Won52-week high 18,20052-week low 2,580

1-month return4.0Point

1m +5.12% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

12 totalPositive 2Neutral 10Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08
Neutral주식등의대량보유상황보고서(일반)2026-06-08
Neutral주식등의대량보유상황보고서(일반)2026-06-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-08